Lexaria Bioscience Corp. LXRP Archives - Page 4 of 27

FridayDec 13, 2019 3:32 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Focuses on Pioneering New Technologies

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is a global innovator in drug-delivery platforms focused on its patented DehydraTECH-based, drug-delivery technology and formulation development. A recent article discussing the company reads, “Earlier this year, Lexaria moved into its new head office that includes a Health Canada-licensed research and development laboratory that is being used to conduct world-leading research into drug-delivery methods and improvements. In addition to accelerating research in the company’s DehydraTECH drug-delivery platform, Lexaria is also considering issuing a limited commercial release of DehydraTECH version 2.0, which has been shown to deliver 811% more CBD into animal blood than generic…

FridayDec 06, 2019 12:50 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Names Senior Advisor to Outline Leadership Strategies

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator with technology that has demonstrated its ability to enhance the oral delivery of nicotine, recently appointed Gregg Smith, founder of a New York-based culture-tech, venture investment firm, as senior advisor to help define LXRP’s leadership strategies. An article discussing the company reads, “‘I am passionate about creating a smokeless future and recognize that the consumption methods of nicotine and cannabis will change,’ Smith stated in the news release (http://ibn.fm/Srpvg). ‘Lexaria’s technology, DehydraTECH(TM), will completely disrupt and improve the consumption and delivery of oral nicotine, CBD and cannabis. Lexaria’s recognition of the…

ThursdayDec 05, 2019 11:54 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Makes Edible Drug Delivery Platform Even Faster

Lexaria Bioscience is a company that is passionate about establishing alternatives to inhalation for rapid-response drug substance delivery in order to eliminate the lung harm that smoking or vaping may cause Lexaria’s DehydraTECH platform has generated numerous patents with more pending as a way to provide quick substance delivery to the user’s bloodstream and better access through the blood-brain barrier Lexaria recently announced it had further improved DehydraTECH, as demonstrated in testing that showed early pilot-stage human trial participants began to note edible THC effects in under 10 minutes – more rapidly than the previous DehydraTECH formulation Prior technology testing…

WednesdayDec 04, 2019 2:17 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Drug Delivery Platform Proven to Enhance Absorption of Bioactive Compounds

DehydraTECH™ is patent protected for multiple Active Pharmaceutical Ingredients (APIs) including hemp oil CBD and cannabis, nicotine, non-steroidal anti-inflammatory drugs, and fat-soluble vitamins Lexaria has 16 patents granted and over 60 patent applications pending worldwide DehydraTECH™ shown to facilitate rapid uptake and highly targeted delivery of pharmaceuticals to the brain Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, is accelerating its patented DehydraTECH based drug delivery technology and formulation development. Funding received from the first tranche of Lexaria’s previously announced private placement of units, issued at a price of $0.45 per unit, realized gross…

TuesdayNov 26, 2019 2:15 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Set to Profit from FDA’s MRTP Pathway Announcement

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator with technology that has demonstrated its ability to enhance the oral delivery of nicotine, is positioned to benefit from the FDA’s recent announcement that it had authorized the marketing of eight smokeless tobacco products through the modified-risk, tobacco-product (“MRTP”) pathway (http://ibn.fm/3hCAN). An article discussing the company reads, “The FDA approval of the ‘modified risk’ claims was made after reviewing scientific evidence submitted by the manufacturer of the products. The approvals, which are product specific and expire after five years, do not mean the products come with no health risks. Nicotine-based products are…

ThursdayNov 21, 2019 10:22 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Enhanced Technology Shows Rapid Onset of Action in Under 10 Minutes

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its development of additional enhancements for its industry-leading DehydraTECH(TM) platform that delivers THC onset of action in less than 10 minutes in human pilot testing. According to the update, volunteers in recent human subjective pilot tests reported onset in less than 10 minutes from edibles formulated with this latest DehydraTECH innovation. This enhanced version of the delivery platform shows onset that is roughly twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations. To view the full press release,…

ThursdayNov 14, 2019 2:12 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Appoints Strategic Advisor, Advances Tech Platform as Alternative to Smoking and Vaping

Lexaria Bioscience is dedicated to providing healthful alternatives to drug-substance inhalation by providing an edible technology that works as effectively as smoking or vaping at getting substances into the bloodstream The company’s DehydraTECH platform has been licensed to multiple companies in the cannabis and tobacco industries, and Canada’s recent nationwide legalization of cannabis edibles is expected to open even more of a market Gregg Smith, the founder of a New York-based "culture tech" venture investment firm, has joined Lexaria as a senior advisor to help define the company’s leadership strategies Innovations in drug delivery are making the wellness product market…

WednesdayNov 13, 2019 3:16 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advances Development of Proprietary Drug-Delivery Platform

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, continues to progress the development and patenting of its DehydraTECH(TM) platform. An article discussing the company reads, “The DehydraTECH(TM) drug-delivery platform can be used to deliver substances in edible or in beverage form, and in capsules, pills, syrups and more. Brands in both Canada and the United States have licensed DehydraTECH to make their CBD and cannabis beverages best-in-class. . . . Not only is ingestion a much safer form of drug delivery, but DehydraTECH also delivers the active ingredient of the substance at a rate that is…

WednesdayNov 06, 2019 12:56 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH Drug-Delivery Platform May Ease Overdose Risk in Cannabis Edibles

Edible cannabis products are absorbed slowly Consumers of cannabis edibles often mistake the delayed effect for insufficiency, leading to overdosing DehydraTECH drug-delivery platform speeds up absorption, reducing overdose risk Sometimes what is gained on the roundabouts is lost on the swings, to paraphrase an old saying. Cannabis liberalization has introduced an entirely new sector to the food and beverage industry – namely, cannabis edibles such as cookies, chocolates and candies. It’s a sector that appears poised for growth. But as mass consumption increases, a hidden problem is emerging (http://ibn.fm/E1DSr). Because bioabsorption rates via edibles are slower than those via smoking,…

TuesdayNov 05, 2019 9:22 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Names New Senior Advisor

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, this morning announced the appointment of Gregg Smith as a Senior Advisor for the company. Smith is the founder of Evolution VC Partners (www.EvolutionVCP.com), a New York-based “culture tech” venture investment firm with over 90 portfolio companies. Through his LLC, Smith is acquiring an equity position in LXRP by participating in the company's recently announced private placement financing of $0.45 units. “I am passionate about creating a smokeless future and recognize that the consumption methods of nicotine and cannabis will change. Lexaria's technology, DehydraTECH(TM), will completely disrupt and…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP